Key Highlights
- Timothy P. Walbert: Former Chairman, President & CEO of Horizon Therapeutics, instrumental in $28.3 billion acquisition by Amgen.
- Ian F. Smith: Former Executive Vice President and COO of Vertex Pharmaceuticals, pivotal in transforming Vertex into a global biotech leader.
- Both Directors bring a combined 60+ years of leadership in the biopharma industry.
- Appointment strengthens Odyssey’s position in advancing next-generation immunomodulators for inflammatory diseases.
Source: Business Wire
Notable Quotes
- “Tim’s legacy in the industry is hallmarked by the acquisition, development and commercialization of numerous life-changing therapies at Horizon that led to one of the largest biopharma acquisitions in recent years.” — Jeff Leiden, M.D., Ph.D., Chairman at the Odyssey Board
- “As we advance our lead programs into and through the clinic… we look forward to leveraging the insights of Ian, Tim, and the rest of our accomplished Board.” — Gary D. Glick, Ph.D., CEO at Odyssey Therapeutics
SoHC's Take
Odyssey Therapeutics’ appointment of industry veterans Timothy Walbert and Ian Smith marks a strategic step toward solidifying its leadership in precision immunomodulators for inflammatory diseases. Their combined experience in guiding companies through growth, strategic acquisitions, and commercialization will be invaluable as Odyssey expands its clinical and research-stage programs. The wealth of knowledge Walbert brings from his success with Horizon’s multi-billion-dollar acquisition by Amgen and Smith’s experience transitioning Vertex into a global leader provides a robust foundation for Odyssey’s future ambitions. This move underscores Odyssey’s commitment to driving innovative therapies that improve patient outcomes.
